Actively Recruiting
EMVI as a Determinant of Metastasis in Colorectal Cancer
Led by Imperial College London · Updated on 2024-11-01
100
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years. This is normally due to spread of the cancer to other organs (called metastases). Much of the current research focuses on use of additional treatments such as radiotherapy and chemotherapy before or after surgery (adjuvant treatment). It is of vital importance that patients who would benefit from adjuvant treatment can be accurately identified. At the moment, the system used locally to do this places emphasis on the presence of affected lymph nodes (glands). This is because doctors believe that cancer spreads to other organs through the lymphatic system. However, recent studies have suggested that this is not the case. It is believed that cancer spreads to other organs through the blood stream rather than the lymph node system. This research will look at the genetic material in tumours and metastases as well as in areas of blood vessel invasion and lymph nodes. The analysis will allow us to build a 'family tree' of the tumour and allow us to map the pathway by which the tumour spreads. Tissue samples already collected through a patient's routine care will be used for this study. If the spread through the blood vessels is proven, this would change the way in which patients are selected for treatment and allow development of new treatments to target these pathways.
CONDITIONS
Official Title
EMVI as a Determinant of Metastasis in Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 16 years or older with colorectal cancer
- Colon or rectum surgically removed
- Distant metastases surgically removed
- Preoperative CT or MRI scans available for review
You will not qualify if you...
- Complete pathological response in the primary tumor
- Local resection of the primary tumor
- Insufficient tissue sample for analysis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hampshire Hospitals Nhs Foundation Trust
Basingstoke, Hampshire, United Kingdom, RG24 9NA
Actively Recruiting
Research Team
C
Caroline Martin
CONTACT
S
Syvella Ellis
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here